$0.02
0.00% day before yesterday
Nasdaq, Nov 28, 04:07 pm CET
ISIN
US36338D1081
Symbol
GRTX

Galera Therapeutics Inc Stock price

$0.02
-0.01 20.37% 1M
-0.00 11.89% 6M
-0.02 53.06% YTD
-0.02 41.89% 1Y
-1.58 98.66% 3Y
-10.90 99.80% 5Y
-11.98 99.82% 10Y
-11.98 99.82% 20Y
Nasdaq, Closing price Fri, Nov 28 2025
+0.00 1.90%
ISIN
US36338D1081
Symbol
GRTX
Industry

Key metrics

Basic
Market capitalization
$1.6m
Enterprise Value
$147.5m
Net debt
$145.8m
Cash
$5.2m
Shares outstanding
75.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | 0.0
EV/Sales
- | 1.2
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
-1,422.3%
Return on Equity
13.2%
ROCE
-253.9%
ROIC
-
Debt/Equity
-1.0
Financials (TTM | estimate)
Revenue
$0.0 | $127.0m
EBITDA
$-14.5m | $-44.7m
EBIT
$-14.5m | $-44.7m
Net Income
$-13.2m | $-60.1m
Free Cash Flow
$-8.3m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
46.6% | -216.1%
EBIT
47.1% | -216.3%
Net Income
54.7% | -217.0%
Free Cash Flow
72.2%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -35.2%
EBIT
-
Net
- | -47.3%
Free Cash Flow
-
More
EPS
$-0.1
FCF per Share
$-0.1
Short interest
5.3%
Employees
3
Rev per Employee
$0.0
Show more

Is Galera Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,070 stocks worldwide.

Galera Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Galera Therapeutics Inc forecast:

4x Hold
57%
3x Sell
43%

Analyst Opinions

7 Analysts have issued a Galera Therapeutics Inc forecast:

Hold
57%
Sell
43%

Financial data from Galera Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 8.06 8.06
37% 37%
-
- Research and Development Expense 0.41 0.41
97% 97%
-
-14 -14
47% 47%
-
- Depreciation and Amortization 0.01 0.01
96% 96%
-
EBIT (Operating Income) EBIT -14 -14
47% 47%
-
Net Profit -13 -13
55% 55%
-

In millions USD.

Don't miss a Thing! We will send you all news about Galera Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Galera Therapeutics Inc Stock News

Neutral
GlobeNewsWire
about one month ago
Galera has entered into an Asset Purchase Agreement with Toronto-based Biossil for Galera's dismutase mimetics portfolio, including all avasopasem and rucosopasem formulations and indications. The agreement includes 1) an upfront payment of $3.5 million, 2) potential future regulatory milestones, commercial milestones, and contingent value rights of up to $105 million.

Company Profile

Galera Therapeutics, Inc. operates as a clinical-stage biotechnology company. It focuses on developing and commercializing a pipeline of novel, proprietary therapeutics for cancer. The firm involves in the prevention of radiation-induced toxicity, including mucositis and the treatment of fibrosis and cancer. Its product candidate, GC4419, reduces severe oral mucositis in patients with head and neck cancer undergoing radiation therapy and also receiving cisplatin, a chemotherapy drug. The company was founded by Robert A. Beardsley, Randy W. Weiss, and Dennis P. Riley in 2009 and is headquartered in Malvern, PA.

Head office United States
CEO J. Sorensen
Employees 3
Founded 2009
Website www.galeratx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today